Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation

Akinobu Takaki, Takahito Yagi, Yoshiaki Iwasaki, Hiroshi Sadamori, Hiroyoshi Matsukawa, Hiroaki Matsuda, Susumu Shinoura, Yuzo Umeda, Yasuhiro Miyake, Ryou Terada, Haruhiko Kobashi, Kohsaku Sakaguchi, Noriaki Tanaka, Yasushi Shiratori

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Hepatitis B immunoglobulin (HBIg) and lamivudine combination has been accepted as the best way to control hepatitis B recurrence after liver transplantation. However, the optimal dose of HBIg and the target titer of hepatitis B surface antibody (HBsAb) remain unclear. We report our satisfactory experience with high-dose HBIg in the early period followed by low-dose HBIg with lamivudine. Subjects comprised five patients with fulminant hepatitis (FH) and 18 patients with liver cirrhosis (LC) who underwent liver transplantation. HBIg at a dosage of 200 IU/kg per day was administered for one week postoperatively. Thereafter, HBIg was administered only for HBsAb titer

Original languageEnglish
Pages (from-to)231-233
Number of pages3
JournalTransplantation
Volume83
Issue number2
DOIs
Publication statusPublished - Jan 2007

    Fingerprint

Keywords

  • Hepatitis B
  • Hepatitis B immunoglobulin
  • Lamivudine
  • Liver transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this